AnaptysBioは,インタビュアーの販売と負の利益にもかかわらず,強いQ3収益を報告した後,52週連続で急上昇した. AnaptysBio soared to a 52-week high after reporting strong Q3 earnings, despite insider sales and negative profits.

Anaptys Bio (ANAB) は,11月4日,強大なQ3収益を0.52 EPSで報告した後,52週連続で5.2ドルに増加し,同社は5.98ドルを突破した. AnaptysBio (ANAB) surged to a 52-week high of $52.00, closing at $51.98, after reporting strong Q3 earnings on November 4 with $0.52 EPS—well above the expected loss of $1.06—and $76.32 million in revenue, far exceeding the $15.83 million estimate. 分析者は,負の収益性指標にもかかわらず,株の買い戻し権限と低株の変動を理由に,目標値55.40ドルで"適度な買い"の評価を維持しています. Despite negative profitability metrics, analysts maintain a consensus "Moderate Buy" rating with a $55.40 target, citing a share repurchase authorization and low stock volatility. 12月のインサイダー販売は 50%以上所有権を削減しましたが 免疫学と炎症に対する抗体治療を進めているのです Insider sales in December reduced ownership by over 50%, but the company continues advancing antibody therapies for immunology and inflammation.